Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
|
SSR69071: A highly potent elastase inhibitor More than one
million new and recurrent cases of coronary attack occurred in the US in 1998.
Forty percent of these patients died, 220,000 before even reaching hospital,
making coronary heart disease the single leading cause of death in America. In
the event of coronary attack the primary aim is to reverse ischemia, limit
infarct size, reduce cardiac work and over the longer-term, to prevent
recurrence. Immediate treatment of myocardial infarction includes the use of
thrombolytics to reverse ischemia. Human leukocyte
elastase (HLE) is a proteinase, capable of degrading a variety of proteins.
Under normal circumstances, the proteolytic activity of HLE is effectively
controlled by its natural inhibitors. However, an imbalance between elastase
and its endogenous inhibitors may result in several pathophysiological states
such as chronic inflammatory diseases, cardiovascular disorders and chronic
obstructive pulmonary disease (including emphysema and chronic bronchitis).
The therapeutic targeting of HLE as well as other key targets in the context
of COPD is reviewed in our state of the art COPD dossier. SSR69071 is a
potent (0.02nM) inhibitor of HLE that exhibits oral activity in the mg/kg
range. SSR69071 decreases significantly the acute lung haemorrhage induced by
HLE as well as carrageenan and HLE-induced paw oedema in rats Neutrophil
elastase contributes to the severity of cardiac damage following coronary
ischemia and reperfusion. Thus Sanofi-Synthelabo researchers have recently
evaluated the effect of SSR69071 on infarct size in anaesthetized rabbits with
coronary ischemia/reperfusion injury. SSR69071 reduced cardiac infarct size
when administered before ischemia (-39%, P<0.05) or just prior to
reperfusion (-37%, P<0.05). This cardioprotective activity was associated
with inhibition of cardiac elastase. Entry date March, 2003 Adapted from Bidouard et al, Eur J Pharmacol 2003 Feb 7;461(1):49-52.
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk Projects such as these are overviewed in full DiscoveryDossiers. LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
